Table 2 Predicted upstream regulators.

From: Deducing signaling pathways from parallel actions of arsenite and antimonite in human epidermal keratinocytes

Regulator

p-value As

p-value Sb

Prediction

A. Transcriptional Analysis

OSM

1.56E-24

5.72E-23

Activated by Sb

Dexamethasone

7.18E-23

7.99E-26

No prediction

NFE2L2

2.73E-21

6.96E-21

Activated by As and Sb

TNFα

1.78E-17

3.83E-21

Activated by Sb

Arsenic trioxide

1.57E-16

(1.70E-11)

Activated by As and Sb

MYC

(1.18E-13)

9.57E-18

No prediction

B. Proteomic Analysis

MYC

2.83E-16

3.44E-19

No prediction

ROCK2

5.04E-16

3.47E-15

Inhibited by As and Sb

FOS

1.09E-14

(4.40E-11)

No prediction

JUN

3.35E-13

(7.96E-10)

No prediction

EFNA4

3.38E-13

5.84E-16

Inhibited by As and Sb

17-Beta-estradiol

(1.09E-12)

9.14E-16

No prediction

EFNA3

(2.74E-11)

4.86E-14

Inhibited by As and Sb

  1. Summary of IPA predicted upstream regulators based on differentially expressed genes (A) or proteins (B). The top five predicted upstream regulators are sorted by p-value for changes due to arsenite treatment (As), which are shown merged in the first column. The second column shows p-values for analysis of untreated vs. antimonite-treated samples (Sb). The top five predicted upstream regulators did not overlap completely for arsenite and antimonite treated samples. When a regulator was predicted, but was not in the list of the top five, p-values are shown in parentheses. The last column indicates whether the regulator is predicted to be activated or inhibited or whether no prediction was made.
Back to article page